natgillin/translations-raw huggingface dataset:
Dokumentationen for virkningen af REZOLSTA en gang dagligt er baseret på analysen af 48-ugers data fra studiet GS-US-216-130 med ART-naive og ART-erfarne patienter, studiet TMC114FD2HTX3001 med ART-naive patienter og to fase III-studier, ARTEMIS og ODIN, udført med darunavir/ritonavir 800/100 mg dagligt hos henholdsvis ART-naive og ART-erfarne patienter. 
The evidence of efficacy of REZOLSTA once daily is based on the analysis of 48 week data from trial GS-US-216-130 in ART-naïve and ART-experienced patients, trial TMC114FD2HTX3001 in ART-naïve patients, and two Phase III trials ARTEMIS and ODIN conducted with darunavir/ritonavir 800/100 mg q.d.
Kombination af colchicin og REZOLSTA er kontraindiceret hos patienter med nedsat nyreeller leverfunktion (se pkt. 
The combination of colchicine and REZOLSTA is contraindicated in patients with renal or hepatic impairment (see section 4.3).
I 96-ugers-analysen svarede sikkerhedsprofilen for darunavir/ritonavir 800/100 mg en gang dagligt hos behandlingsnaive patienter til profilen for darunavir/ritonavir 600/100 mg to gange dagligt hos behandlingserfarne patienter med undtagelse af kvalme, der sås hyppigere hos behandlingsnaive patienter. 
In the 96 week analysis, the safety profile of darunavir/ritonavir 800/100 mg once daily in treatment-naïve subjects was similar to that seen with darunavir/ritonavir 600/100 mg twice daily in treatment-experienced subjects except for nausea which was observed more frequently in treatment-naïve subjects.
I henhold til TLOVR-algoritmen (time to loss of viral response) I henhold til LOCF (last observation carried forward) 
Imputations according to the TLOVR algorithm Last Observation Carried Forward imputation
Separate studier med darunavir/ritonavir og cobicistat tyder på, at dosisjustering ikke er nødvendig hos patienter med let (Child-Pugh klasse A) eller moderat (Child-Pugh klasse B) nedsat leverfunktion. 
Separate trials of darunavir/ritonavir and cobicistat suggest no dose adjustment is recommended in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment, however, REZOLSTA should be used with caution in these patients.
Tag altid lægemidlet nøjagtigt efter lægens, apotekspersonalets eller sundhedspersonalets anvisning. 
Always use this medicine exactly as your doctor, pharmacist or nurse has told you.
Tabletten skal synkes hel for at sikre administration af hele dosen af både darunavir og cobicistat. 
To ensure administration of the entire dose of both darunavir and cobicistat, the tablet should be swallowed whole.
Hver tablet indeholder 800 mg darunavir (som ethanolat) og 150 mg cobicistat. 
Each tablet contains 800 mg of darunavir (as ethanolate) and 150 mg cobicistat.
(OATP1B- og CYP3A-hæmning) 
(OATP1B and CYP3A inhibition)
Bivirkninger med darunavir/cobicistat hos voksne patienter 
Adverse reactions with darunavir/cobicistat in adult patients
Emtricitabin/tenofoviralafenamid Tenofoviralafenamid ↔ Tenofovir ↑ 
Tenofovir alafenamide ↔ Tenofovir ↑
REZOLSTA bør ikke anvendes til behandlingserfarne patienter med en eller flere DRV-RAM hiv-1 RNA ≥ 100.000 kopier/ml eller CD4+-celletal < 100 x 10 
REZOLSTA should not be used in treatment-experienced patients with one or more DRV-RAMs or HIV-1 RNA ≥ 100,000 copies/mL or CD4+ cell count < 100 cells x 10
REZOLSTA og antacida kan anvendes samtidig uden dosisjustering. 
REZOLSTA and antacids can be used concomitantly without dose adjustment.
REZOLSTA må derfor ikke anvendes til patienter med svært nedsat leverfunktion (Child-Pugh klasse C) (se pkt. 
Therefore, REZOLSTA must not be used in patients with severe hepatic impairment (Child-Pugh Class C) (see sections 4.3, 4.4 and 5.2).
Ved 48-ugers-analysen blev non-inferioritet i virologisk respons over for darunavir/ritonavirbehandlingen, defineret som procentdelen af patienter med plasma-hiv-1 RNA < 50 kopier/ml, påvist (ved den forud definerede 12 % non-inferioritetsgrænse) hos begge populationer (”Intent-To-Treat” og ”On Protocol”). 
Non-inferiority in virologic response to the darunavir/ritonavir treatment, defined as the percentage of patients with plasma HIV-1 RNA level < 50 copies/mL, was demonstrated (at the pre-defined 12% non-inferiority margin) for both Intent-To-Treat (ITT) and On Protocol (OP) populations in the 48 week analysis.
Nukleos(t)id-revers-transkriptase-hæmmere (NRTI'er) mod hiv Didanosin 
HIV Nucleo(s/t)ide reverse transcriptase inhibitors (NRTIs) Didanosine
Co-administration af REZOLSTA og rifabutin og rifapentin frarådes. 
Co-administration of REZOLSTA with rifabutin and rifapentine is not recommended.
Hver filmovertrukken tablet indeholder 800 mg darunavir (som ethanolat) og 150 mg cobicistat. 
Each film-coated tablet contains 800 mg darunavir (as ethanolate) and 150 mg cobicistat.
Med CD4+celletal < 200 ved baseline Med CD4+celletal ≥ 200 ved baseline Median ændring i CD4+-celletal fra baseline (x 10 
With baseline CD4+ cell count ≥ 200 median CD4+ cell count change from baseline (x 10
Co-administration af REZOLSTA og tadalafil til behandling af pulmonal arteriel hypertension frarådes. 
Co-administration of tadalafil for the treatment of pulmonary arterial hypertension with REZOLSTA is not recommended.
Der er rapporteret om svimmelhed under behandling med regimer, der indeholder darunavir administreret samtidig med cobicistat, hos nogle patienter. 
Dizziness has been reported in some patients during treatment with regimens containing darunavir administered with cobicistat and should be borne in mind when considering a patient's ability to drive or operate machinery.
Lægemidler, der påvirker eksponeringen for darunavir/cobicistat 
Medicinal products that affect darunavir/cobicistat exposure
Behandling med REZOLSTA under graviditet fører til lav eksponering for darunavir (se pkt. 
Treatment with REZOLSTA during pregnancy results in low darunavir exposure (see sections 4.4 and 5.2).
Det forventes ikke, at cobicistat hæmmer CYP1A2, CYP2B6, CYP2C8, CYP2C9 eller CYP2C19, eller at det inducerer CYP1A2, CYP3A4, CYP2C9, CYP2C19, UGT1A1 eller P-gp (MDR1). 
Cobicistat is not expected to induce CYP1A2, CYP3A4, CYP2C9, CYP2C19, UGT1A1, or P-gp (MDR1).
Patienter, der ikke fuldførte behandlingen, betragtes som havende behandlingssvigt, dvs. patienter, der afbrød behandlingen i utide, medregnes med en ændring, der tillægges størrelsen 0. 
Non completer is failure imputation: patients who discontinued prematurely are imputed with a change equal to 0
Hiv-1 RNA < 50 kopier/ml Med hiv-1 RNA (kopier/ml) ved baseline 
HIV-1 RNA < 50 copies/mL With Baseline
Samtidig infektion med hepatitis B og/eller hepatitis C Der var utilstrækkelige farmakokinetiske data i de kliniske studier til at bestemme virkningen af hepatitis B- og/eller C-virusinfektion på darunavirs og cobicistats farmakokinetik (se pkt. 
There were insufficient pharmacokinetic data in the clinical trials to determine the effect of hepatitis B and/or C virus infection on the pharmacokinetics of darunavir and cobicistat (refer to sections 4.4 and
Co-administration af domperidon og REZOLSTA er kontraindiceret. 
Co-administration of domperidone with REZOLSTA is contraindicated.
Der skal udvises forsigtighed ved samtidig brug af REZOLSTA og PDE-5hæmmere til behandling af erektil dysfunktion. 
Concomitant use of PDE-5 inhibitors for the treatment of erectile dysfunction with REZOLSTA should be done with caution.
I henhold til LOCF (last observation carried forward) 
Last Observation Carried Forward imputation
Det virologiske respons, defineret som procentdelen af patienter med plasma-hiv-1 RNA < 50 kopier/ml, ved behandling med darunavir/ritonavir 800/100 mg en gang dagligt, viste sig efter 48 uger at være non-inferiørt (ved den forud definerede 12 % grænse for non-inferioritet) sammenlignet med darunavir/ritonavir 600/100 mg to gange dagligt hos både ITT- og OP-populationer. 
At 48 weeks, virologic response, defined as the percentage of patients with plasma HIV-1 RNA level < 50 copies/mL, with darunavir/ritonavir 800/100 mg once daily treatment was demonstrated to be non-inferior (at the pre-defined 12% non-inferiority margin) compared to darunavir/ritonavir 600/100 mg twice daily for both ITT and OP populations.
TMC114FD2HTX3001 er et randomiseret, aktivt kontrolleret, dobbeltblindt fase III-studie til vurdering af virkningen og sikkerheden af darunavir/cobicistat/emtricitabin/tenofoviralafenamid kontra fastdosis-kombination af darunavir/cobicistat + emtricitabin/tenofovirdisoproxilfumarat. 
Efficacy of darunavir/cobicistat fixed-dose combination 800/150 mg once daily in ART-naïve patients TMC114FD2HTX3001 is a randomized, active-controlled, double blind, Phase III trial to evalate the efficacy and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide versus darunavir/cobicistat fixed-dose combination + emtricitabine/tenofovir disoproxil fumarate.
REZOLSTA og raltegravir kan anvendes uden dosisjusteringer. 
REZOLSTA and raltegravir can be used without dose adjustments.
fra baseline ved uge 2 og -9,6 ml/min. 
The mean eGFRCG change from baseline was -9.6 mL/min at week 2, and -9.6 mL/min at week 48.
REZOLSTA kan anvendes sammen med disse NRTI-midler uden dosisjustering. 
REZOLSTA can be used with these NRTIs without dose adjustment.
REZOLSTA bør ikke anvendes til patienter med en eller flere mutationer associeret med darunavirresistens (DRV-RAM), hiv-1 RNA ≥ 100.000 kopier/ml eller CD4+-celletal < 100 x 10 celler/l (se pkt. 
REZOLSTA should not be used in patients with one or more darunavir resistance associated mutations (DRV-RAMs) or HIV-1 RNA ≥ 100,000 copies/mL or CD4+ cell count < 100 cells x 10
REZOLSTA 800 mg/150 mg tabletter darunavir/cobicistat 
REZOLSTA 800 mg/150 mg tablets darunavir/cobicistat
Patienter co-inficeret med hepatitis B og/eller hepatitis C Der foreligger kun begrænsede oplysninger om brug af REZOLSTA hos patienter co-inficeret med hepatitis B og/eller C. Blandt 1.968 behandlingserfarne patienter, der fik darunavir coadministreret med ritonavir, 600/100 mg to gange dagligt, havde 236 patienter også hepatitis B eller C. Disse patienter var mere tilbøjelige til at have forhøjede hepatiske aminotransferaser ved baseline og efter behandlingsstart end patienter uden kronisk viral hepatitis (se pkt. 
Among 1,968 treatment-experienced patients receiving darunavir co-administered with ritonavir 600/100 mg twice daily, 236 patients were co-infected with hepatitis B or C. Co-infected patients were more likely to have baseline and treatment emergent hepatic transaminase elevations than those without chronic viral hepatitis (see section 4.4).
Co-administration af REZOLSTA og efavirenz frarådes. 
Co-administration of REZOLSTA and efavirenz is not recommended.
- colchicin (til behandling af urinsur gigt eller familiær middelhavsfeber). 
Colchicine (if you have kidney/liver problems) to treat gout or familial Mediterranean fever The combination product lopinavir/ritonavir anti-HIV medicine
Hvis du har taget for mange REZOLSTA Kontakt straks din læge, apotekspersonalet eller sundhedspersonalet. 
If you take more REZOLSTA than you should Contact your doctor, pharmacist or nurse immediately.
Med CD4+-celletal (x 10 
With Baseline CD4+ cell count (x 10
Klinisk monitorering anbefales ved co-administration af REZOLSTA og disse betablokkere, og lavere dosis af disse betablokkere bør overvejes. 
Clinical monitoring is recommended when co-administering REZOLSTA with beta-blockers and a lower dose of the beta-blocker should be considered.
4.5) - sildenafil til behandling af pulmonal arteriel hypertension, avanafil - simvastatin, lovastatin og lomitapid (se pkt. 
see section 4.5) - sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil - simvastatin, lovastatin and lomitapide (see section 4.5) - dabigatran, ticagrelor.
Interaktionsprofilen for darunavir afhænger af, om ritonavir eller cobicistat benyttes som farmakokinetisk forstærker. 
The interaction profile of darunavir depends on whether ritonavir or cobicistat is used as pharmacokinetic enhancer, therefore there may be different recommendations for the use of darunavir with concomitant medicine.
Ved co-administration er terapeutisk lægemiddelmonitorering af det immunsupprimerende middel nødvendig. 
Therapeutic drug monitoring of the immunosuppressive agent must be done when co-administration occurs.
Kombinationen af rifampicin og REZOLSTA er kontraindiceret (se pkt. 
The combination of rifampicin and REZOLSTA is contraindicated (see section 4.3).
4.2 og 4.4). 
6/l (see sections 4.2 and 4.4).
(hæmning af CYP3A) 
(inhibition of CYP3A)
almindelig ikke almindelig pruritus 
Common pruritus
REZOLSTA forventes at øge plasmakoncentrationen af nevirapin. 
REZOLSTA is expected to increase nevirapine plasma concentrations.
REZOLSTAs sikkerhed og virkning hos pædiatriske patienter i alderen 3 til 17 år er ikke klarlagt (se pkt. 
The safety and efficacy of REZOLSTA in paediatric patients aged 3 to 17 years has not been established (see sections 4.4 and 5.3).
Det anbefales at bruge andre trombocythæmmende midler, som ikke påvirkes af CYPhæmning eller -induktion (f.eks. prasugrel se pkt. 
Use of other antiplatelets not affected by CYP inhibition or induction (e.g. prasugrel) is recommended (see section 4.3).
Nedsat nyrefunktion REZOLSTA er ikke undersøgt hos patienter med nedsat nyrefunktion. 
Renal impairment REZOLSTA has not been investigated in patients with renal impairment.
lopinavir/ ritonavir 800/200 mg dagligt N=346 
lopinavir/ ritonavir 800/200 mg per day N = 346
REZOLSTA og didanosin kan anvendes uden dosisjustering. 
REZOLSTA and didanosine can be used without dose adjustments.
Baseret på teoretiske overvejelser kan REZOLSTA muligvis øge plasmakoncentrationen af disse analgetika. 
Based on theoretical considerations REZOLSTA may increase plasma concentrations of these analgesics.
Co-administration af REZOLSTA og dapoxetin er kontraindiceret. 
Co-administration of REZOLSTA with dapoxetine is contraindicated.
Din læge vil muligvis foretage yderligere test. - kortikosteroider, herunder betamethason, budesonid, fluticason, mometason, prednison og triamcinolon. 
- Corticosteroids including betamethasone, budesonide, fluticasone, mometasone, prednisone,
Co-administration af REZOLSTA og disse antiepileptika er kontraindicerede (se pkt. 
Co-administration of REZOLSTA and these anticonvulsants is contraindicated (see section 4.3).
Behandling med REZOLSTA bør ikke initieres hos patienter med kreatininclearance under 70 ml/min, hvis dosisjustering på basis af kreatininclearance er nødvendigt for et samtidigt administreret lægemiddel (f.eks. emtricitabin, lamivudin, tenofovirdisoproxil (som fumarat, fosfat eller succinat) eller adefovirdipivoxil) (se pkt. 
REZOLSTA should not be initiated in patients with creatinine clearance less than 70 mL/min when co-administered with one or more agent requiring dose adjustment based on creatinine clearance (e.g. emtricitabine, lamivudine, tenofovir disoproxil (as fumarate, phosphate or succinate) or adefovir dipivoxil) (see sections 4.2, 4.8 and 5.2).
Metabolisme og ernæring almindelig anoreksi, hyperkolesterolæmi, hypertriglyceridæmi ikke almindelig diabetes mellitus, dyslipidæmi, hyperglykæmi, hyperlipidæmi 
Metabolism and nutrition disorders Common anorexia, hypercholesterolaemia, hypertriglyceridaemia
Triazolam eller oral (taget gennem munden) midazolam som sovemiddel og/eller til at afhjælpe angst 
Triazolam or oral (taken by mouth) midazolam to help you sleep and/or relieve anxiety Sildenafil to treat a heart and lung disorder called pulmonary arterial hypertension.
Baseret på teoretiske overvejelser forventes REZOLSTA at øge plasmakoncentrationen af antimykotika, og plasmakoncentrationen af darunavir og/eller cobicistat kan øges af de pågældende antimykotika. 
Based on theoretical considerations REZOLSTA is expected to increase these antifungal plasma concentrations, and darunavir and/or cobicistat plasma concentrations may be increased by the antifungals.
Baseret på teoretiske overvejelser forventes REZOLSTA at øge koncentrationen af clonazepam. 
Based on theoretical considerations REZOLSTA is expected to increase concentrations of clonazepam.
Genotypebestemmelse skal være vejledende for brugen af REZOLSTA (se pkt. 
Genotypic testing should guide the use of REZOLSTA (see sections 4.2, 4.4 and 5.1).
Baseret på teoretiske overvejelser forventes REZOLSTA at øge plasmakoncentrationen af disse sedativa/hypnotika. 
Based on theoretical considerations REZOLSTA is expected to increase these sedative/hypnotic plasma concentrations.
Co-administration af REZOLSTA og nevirapin frarådes. 
Co-administration of REZOLSTA and nevirapine is not recommended.
Behandlingsnaive darunavir/cobicistat 800/150 mg en gang dagligt + emtricitabine/tenofovirdisoproxilfumarat N = 363 
Treatment-naïve darunavir/cobicistat 800/150 mg once daily + emtricitabine/tenofovir disoproxil fumarate N = 363
Baseret på teoretiske overvejelser forventes nevirapin at nedsætte plasmakoncentrationen af darunavir og/eller cobicistat (CYP3A-induktion). 
Based on theoretical considerations nevirapine is expected to decrease darunavir and/or cobicistat plasma concentrations, (CYP3A induction).
(CYP3A-, CYP2D6- og/eller P-gp-hæmning) 
(CYP3A, CYP2D6 and/or P-gp inhibition)
Der blev ikke observeret krydsresistens med andre hiv-PI'er i de virologiske svigt fra studiet GS-US216-130. 
In the virologic failures of the GS-US-216-130 trial no cross-resistance with other HIV PIs was observed.
REZOLSTA 800 mg/150 mg filmovertrukne tabletter darunavir/cobicistat 
REZOLSTA 800 mg/150 mg film-coated tablets darunavir/cobicistat
Du skal straks informere din læge, så du kan få den nødvendige behandling, hvis du bemærker symptomer på infektion eller andre symptomer, såsom muskelsvaghed, svaghed begyndende i hænder og fødder, og som bevæger sig op igennem kroppen, hjertebanken, rysten eller hyperaktivitet. 
If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately so you can be given the necessary treatment.
Samtidig brug af REZOLSTA og lovastatin eller simvastatin er kontraindiceret (se pkt. 
Concomitant use of REZOLSTA with lovastatin and simvastatin is contraindicated (see section 4.3).
I REZOLSTA-armen i fase III-studiet TMC114FD2HTX3001 var den gennemsnitlige ændring i eGFRCG fra baseline -11,1 ml/min. 
In the REZOLSTA arm of Phase III trial TMC114FD2HTX3001, mean eGFRCG change from baseline was -11.1 mL/min at week 48 and mean eGFRcystatin C change from baseline was +2.9 mL/min/1.73 m² at week 48.
REZOLSTA og tenofovirdisoproxil kan anvendes uden dosisjustering. 
REZOLSTA and tenofovir disoproxil can be used without dose adjustments.
- buspiron, clorazepat, diazepam, estazolam, flurazepam, zolpidem og midazolam brugt som injektion (medicin til behandling af søvnforstyrrelser og/eller angst). 
- Bosentan (to treat high blood pressure in the pulmonary circulation) - Buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem, midazolam when used as injection (medicines to treat trouble with sleeping and/or anxiety) - Metformin (to treat type 2 diabetes) - Fentanyl, oxycodone, tramadol (to treat pain).
REZOLSTA bør ikke anvendes til pædiatriske patienter under 3 år (se pkt. 
REZOLSTA should not be used in paediatric patients below 3 years of age (see sections 4.2 and 5.3).
Virkning af darunavir 800 mg en gang dagligt co-administreret med 100 mg ritonavir en gang dagligt hos ART-erfarne patienter 
Efficacy of darunavir 800 mg once daily co-administered with 100 mg ritonavir once daily in ART-experienced patients
Der skal udvises forsigtighed ved kombination af disse antineoplastika og REZOLSTA. 
Caution should be exercised when combining one of these anti-neoplastic agents with REZOLSTA.
Mave-tarm-kanalen meget almindelig diarré, kvalme almindelig opkastning, abdominalsmerter, abdominal distention, dyspepsi, flatulens ikke almindelig akut pankreatitis, forhøjede pankreasenzymer 
Common vomiting, abdominal pain, abdominal distension, dyspepsia, flatulence
Behandling med REZOLSTA bør ikke initieres hos patienter med kreatininclearance under 70 ml/min, hvis dosisjustering på basis af kreatininclearance for et samtidigt administreret lægemiddel (f.eks. emtricitabin, lamivudin, tenofovirdisoproxilfumarat (som furamat, fosfat eller succinat) eller adefovirdipivoxil) er nødvendig (se pkt. 
REZOLSTA should not be initiated in patients with creatinine clearance less than 70 mL/min, if any co-administered medicinal product (e.g. emtricitabine, lamivudine, tenofovir disoproxil (as fumarate, phosphate or succinate), or adefovir dipivoxil) requires dose adjustment based on creatinine clearance (see sections 4.4, 4.8 and 5.2).
Hos kvinder, der fik REZOLSTA i andet trimester af graviditeten, var de gennemsnitlige intraindividuelle værdier for Cmax, AUC24t og Cmin for total-darunavir hhv. 49 %, 56 % og 92 % lavere i forhold til post partum. 
In women receiving REZOLSTA during the second trimester of pregnancy, mean intra-individual values for total darunavir Cmax, AUC24h and Cmin were 49%, 56% and 92% lower, respectively, as compared with postpartum; during the third trimester of pregnancy, total darunavir Cmax, AUC24h and Cmin values were 37%, 50% and 89% lower, respectively, as compared with postpartum.
Virkningen af darunavir 800 mg en gang dagligt co-administreret med 150 mg cobicistat en gang dagligt hos ART-naive og ART-erfarne patienter 
Efficacy of darunavir 800 mg once daily co-administered with 150 mg cobicistat once daily in ART-naïve and ART-experienced patients
Samtidig administration af REZOLSTA og alfuzosin er kontraindiceret (se pkt. 
Co-administration of REZOLSTA with alfuzosin is contraindicated (see section 4.3).
darunavir/ritonavir 600/100 mg to gange dagligt + OBR N=296 
darunvir/ritonavir 600/100 mg twice daily + OBR N = 296
Virkning af darunavir 800 mg en gang dagligt co-administreret med 100 mg ritonavir en gang dagligt hos ART-naive patienter 
Efficacy of darunavir 800 mg once daily co-administered with 100 mg ritonavir once daily in ART-naïve patients
Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 personer) - symptomer på infektion eller på autoimmune lidelser (immunrekonstitutionsinflammatorisk syndrom (IRIS)) - osteonekrose (hvor knoglevævet dør på grund af manglende blodforsyning til knoglen) - udvikling af bryster hos mænd (gynækomasti) - unormale resultater af blodprøver som for eksempel undersøgelser af bugspytkirtel, højt sukkerniveau, unormale niveauer af "lipider" (fedtstoffer); din læge vil forklare dig om dette - allergiske reaktioner som for eksempel nældefeber (urticaria), svær hævelse af huden og andre væv (oftest læberne eller øjnene) - alvorligt udslæt med blærer og og afskallende hud, især omkring munden, næsen, øjnene og kønsorganerne. 
Uncommon side effects (may affect up to 1 in 100 people) - symptoms of infection or of autoimmune disorders (immune reconstitution inflammatory syndrome) - osteonecrosis (death of bone tissue caused by loss of blood supply to the bone) - enlargement of breasts - abnormal blood test results such as some tests for your pancreas, high level of sugar, abnormal levels of ‘lipids' (fats).
ANTIRETROVIRALE MIDLER MOD HIV Integrasehæmmere 
HIV ANTIRETROVIRALS Integrase strand transfer inhibitors Dolutegravir
Behandlingserfarne darunavir/ritonavir 600/100 mg to gange dagligt N=296 
Treatment-experienced darunavir/ritonavir 600/100 mg twice daily N = 296
Co-administration af REZOLSTA og etravirin frarådes. 
Co-administration of REZOLSTA and etravirine is not recommended.
REZOLSTA bør af sikkerhedsmæssige grunde ikke anvendes til pædiatriske patienter under 3 år (se pkt. 
REZOLSTA should not be used in paediatric patients below 3 years of age because of safety concerns (see sections 4.4 and 5.3).
Baseret på teoretiske overvejelser kan REZOLSTA muligvis øge plasmakoncentrationen af methadon. 
Based on theoretical considerations REZOLSTA may increase methadone plasma concentrations.
Hvis du kommer i tanke om den glemte dosis inden for 12 timer, skal du straks tage den. Skal altid tages sammen med mad. 
If you notice within 12 hours, you must take the tablet immediately.